Edition:
India

Alembic Pharmaceuticals Ltd (ALEM.NS)

ALEM.NS on National Stock Exchange of India

994.75INR
1:47pm IST
Change (% chg)

Rs-0.65 (-0.07%)
Prev Close
Rs995.40
Open
Rs999.50
Day's High
Rs1,009.90
Day's Low
Rs990.00
Volume
248,545
Avg. Vol
487,432
52-wk High
Rs1,128.90
52-wk Low
Rs434.80

Select another date:

Wed, Jul 1 2020

BRIEF-Alembic Pharma Receives US FDA Approval For Doxycycline Hyclate Tablets

* RECEIVED US FOOD & DRUG ADMINISTRATION (USFDA) FINAL APPROVAL FOR DOXYCYCLINE HYCLATE TABLETS USP, 75 MG AND 150 MG Source text for Eikon: Further company coverage:

BRIEF-Alembic Pharmaceuticals Gets US FDA Tentative Approval For Rivaroxaban Tablets

* ALEMBIC PHARMACEUTICALS LTD SAYS RECEIVED US FOOD & DRUG ADMINISTRATION (USFDA) TENTATIVE APPROVAL FOR RIVAROXABAN TABLETS, 10 MG, 15 MG, AND 20 MG. Source text for Eikon: Further company coverage:

BRIEF-Alembic Pharmaceuticals Says JV Got U.S. FDA Approval For Adapalene Gel

* ALEMBIC PHARMACEUTICALS LTD SAYS COMPANY'S JOINT VENTURE, RECEIVED US FOOD AND DRUG ADMINISTRATION FINAL APPROVAL FOR ADAPALENE GEL USP, 0.3%. Source text for Eikon: Further company coverage:

BRIEF-Alembic Pharma Gets EIR For Panelav General Oral Solid Formulation Facility

* GETS ESTABLISHMENT INSPECTION REPORT FOR GENERAL ORAL SOLID FORMULATION FACILITY AT PANELAV Source text for Eikon: Further company coverage:

BRIEF-Alembic Pharmaceuticals Ltd Gets U.S. FDA Final Approval For Deferasirox Tablets

* ALEMBIC PHARMACEUTICALS LTD SAYS RECEIVED US FOOD & DRUG ADMINISTRATION (USFDA) FINAL APPROVAL FOR DEFERASIROX TABLETS, 180 MG. Source text for Eikon: Further company coverage:

BRIEF-India's Alembic Pharmaceuticals March Qtr Consol Net Profit Rises

* MARCH QUARTER CONSOL NET PROFIT 2.22 BILLION RUPEES VERSUS 1.23 BILLION RUPEES YEAR AGO

BRIEF-Alembic Pharma's JV Aleor Dermaceuticals Gets USFDA Nod For Clobetasol Propionate Shampoo

* CO'S JV, ALEOR DERMACEUTICALS, GOT USFDA APPROVAL FOR CLOBETASOL PROPIONATE SHAMPOO, 0.05% Source text for Eikon: Further company coverage:

BRIEF-Alembic Pharmaceuticals JV Co Gets EIR From U.S. FDA

* RECEIVED ESTABLISHMENT INSPECTION REPORT (EIR) FROM UNITED STATES FOOD AND DRUG ADMINISTRATION

BRIEF-FDA Classifies Alembic Pharma's Panelav Formulation Facility As Voluntary Action Indicated

* U.S. FDA CLASSIFIED PANELAV GENERAL ORAL SOLID FORMULATION FACILITY AS VOLUNTARY ACTION INDICATED Source text: (https://bit.ly/2WCnA9B) Further company coverage:

Select another date: